Gains Access to In Vitro Diagnostic Technologies in Development for Use
in Point-of-Care Settings
SOLLENTUNA, Sweden, June 18 /CNW/ -- Johnson & Johnson Nordic AB, a
Johnson & Johnson company, today announced the acquisition of Amic, a
privately held Swedish developer of in vitro diagnostic (IVD) technologies for
use in Point-of-Care (POC) and near-patient settings (outside the physical
facilities of the clinical laboratory). The acquisition will provide
Ortho-Clinical Diagnostics, Inc., a Johnson & Johnson company, with access to
a high performance technology platform -- currently in development in this
rapidly growing area of diagnostics -- that complements its clinical
laboratory, immunohematology and donor screening businesses. As a result of
the acquisition, Johnson & Johnson expects to incur an estimated one-time
after-tax charge of approximately $40 million during the second quarter of
2008 related to the expensing of in-process research and development. Other
terms of the transaction were not disclosed.
Amic is developing technology that uses a chip-based micro-fluidic
platform to enable fully quantitative, immunoassay tests in POC or
near-patient settings. This next-generation technology represents an advance
in an area of diagnostics where double-digit market growth is anticipated.
"This acquisition is a strategic opportunity to develop a Point-of-Care
channel," said Mark Straley, Worldwide Commercial President, Ortho-Clinical
Diagnostics, Inc. "We're committed to bringing novel assays and existing tests
closer to the patient and delivering information to health care professionals
when and where they need it."
"We're excited about the possibilities of touching the lives of patients
by combining our testing technologies with current and future assays of
Ortho-Clinical Diagnostics," said Ove Ohman, founder and CEO, Amic.
About Johnson & Johnson Nordic AB
Johnson & Johnson Nordic AB is a subsidiary of Johnson & Johnson. Based
in Sollentuna, Sweden, Johnson & Johnson Nordic AB is a sales and marketing
company in the Medical Devices & Diagnostics segment.
About Ortho-Clinical Diagnostics, Inc.
Ortho-Clinical Diagnostics, Inc., a Johnson & Johnson company, delivers
high quality in vitro diagnostic products that give health care professionals
around the world the knowledge they need to make better treatment decisions
sooner. The company serves the global transfusion medicine community with
donor screening and blood typing products to help ensure every patient
receives blood that's safe, the right type, and the right unit. Ortho-Clinical
Diagnostics also brings sophisticated information management, testing
technologies, automation and interpretation tools to clinical laboratories
worldwide to help them run more efficiently and improve patient care. For more
information, visit www.orthoclinical.com.
(This press release contains "forward-looking statements" as defined in
the Private Securities Litigation Reform Act of 1995. These statements are
based on current expectations of future events. If underlying assumptions
prove inaccurate or unknown risks or uncertainties materialize, actual results
could vary materially from Johnson & Johnson's expectations and projections.
Risks and uncertainties include general industry conditions and competition;
economic conditions, such as interest rate and currency exchange rate
fluctuations; technological advances and patents attained by competitors;
challenges inherent in new product development, including obtaining regulatory
approvals; domestic and foreign health care reforms and governmental laws and
regulations; and trends toward health care cost containment. A further list
and description of these risks, uncertainties and other factors can be found
in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year
ended December 30, 2007. Copies of this Form 10-K, as well as subsequent
filings, are available online at www.sec.gov, www.jnj.com or on request from
Johnson & Johnson. Johnson & Johnson does not undertake to update any
forward-looking statements as a result of new information or future events or
For further information:
For further information: Press: Linda Fedow, (908) 218-8287, or Teresa
Mueller, +33-1-55-00-4433; Investors: Louise Mehrotra, (732) 524-6491, or Stan
Panasewicz, (732) 524-2524, all for Johnson & Johnson Nordic AB, Web Site: